Objectives: To investigate the efficacy of stereotactic body radiotherapy in oligometastatic urothelial carcinoma with node-only involvement. Methods: We retrospectively collected data on the outcomes of patients who underwent stereotactic body radiotherapy for metastatic node lesions from oligometastatic urothelial carcinoma at Radiotherapy Unit of University Hospital of Parma, Parma, Italy. The investigated outcomes were lesion size, standardized uptake value, overall response rate, lesion control rate, lesion progression-free interval, progression-free survival and overall survival. Results: Among seven patients included in the study, a total of 14 node metastatic lesions were treated with stereotactic body radiotherapy. The mean total dose of stereotactic body radiotherapy was 32 Gy (range 25-40 Gy). At first imaging evaluation, a mean variation of À4% (P = 0.427) in major diameter, À16% (P = 0.048) in minor diameter and -76% in standardized uptake value (P < 0.001) were documented. The overall response rate and lesion control rate were 43% and 100%, respectively. Median lesion progression-free interval, progression-free survival and overall survival were 11.4 months (95% CI 3.4-19.4), 2.9 months (95% CI 2.6-3.1) and 14.9 months (95% CI 12.3-17.5), respectively. Stereotactic body radiotherapy was effective in delaying the beginning of a systemic chemotherapy in four patients. Conclusions: The present findings generate the hypothesis of a possible role for the use of stereotactic body radiotherapy in selected patients with distant node metastases from oligometastatic urothelial carcinoma.
Introduction
Bladder cancer represents the ninth most common neoplasm in the world, 1 with the highest incidence rates observed in men in more developed countries 2 and with a clear cause-effect correlation with tobacco smoking. 3 The most common histological subtype is urothelial carcinoma, occurring in >90% of bladder cancer. 1 Approximately 30% of newly diagnosed cases are muscle-invasive disease, and surgery is the standard treatment choice. Upper tract urothelial carcinoma is relatively uncommon compared with urothelial bladder cancer, but its clinical behavior is definitively more aggressive. 2, 4 At the time of diagnosis, approximately 4% of patients have metastatic urothelial bladder cancer; 4 upper tract urothelial carcinoma occurs as metastatic disease at diagnosis in a wider range of patients, accounting for 20% of cases. 4 Systemic therapy is mandatory in the metastatic setting, and CDDP-based combination chemotherapy is still the preferred first-line option. Despite the high response rates obtained with these regimens, the DoR appears to be very low, with a reported median OS of 9-15 months. 5, 6 Furthermore, not all patients are eligible for platinum-based chemotherapy, because of comorbidities, poor PS and impaired renal function after radical surgery, resulting in potentially suboptimal treatment options for the disease (mono-chemotherapy, CBDCAbased combination chemotherapy or immunotherapy). 7, 8 The role of RT for the treatment of advanced urothelial cancer (both of the bladder and of the upper urinary tract) is controversial. Urothelial carcinoma is known to be relatively radiosensitive. 9 Regarding bladder urothelial carcinoma, preoperative RT has been investigated in prospective trials with the aim of both preventing intraoperative seeding of tumor cells and sterilizing the operative field, 10-13 but only one randomized published trial showed a significant difference in 2-year disease-free survival in favor of adding preoperative RT to cystectomy. 10 For patients not eligible for radical cystectomy, RT with concurrent chemotherapy after TURBT represents a multimodality bladder-sparing approach; CR rates range from 59% to 81%, and treatment-related toxicities are not negligible. 4 RT has also been investigated as an adjuvant treatment alone after radical cystectomy for urothelial bladder carcinoma, and it is a reasonable option in this setting for selected patients (pT3-pT4 N0-2 and positive surgical margins), even if there are no conclusive results about any OS advantage. 4, 14 The use of RT for the treatment of upper urinary tract urothelial carcinoma is still marginal and available data are very limited. 15, 16 In the metastatic setting, RT is often used to treat symptomatic metastases or pelvic recurrence after cystectomy, mainly for palliation of pain and bleeding when a local control cannot be achieved by transurethral manipulation because of extensive local tumor growth. 1, 4, 17 RT alone, according to the National Comprehensive Cancer Network guidelines, can also be considered as a subsequent option for patients with metastatic disease, but data about responses and outcomes are missing. 4 It is known that metastatic disease with node-only involvement and good PS has a better prognosis compared with patients with visceral metastasis (bone, lung and liver) and/or poor PS. 18 Furthermore, urothelial carcinoma with oligometastases (defined as a solitary metastatic organ; number of metastatic lesions of ≤3; the largest diameter of metastatic foci of ≤5 cm; no liver metastases) has a favorable prognosis compared with non-oligometastatic disease. 19 To date, no studies have been carried out to investigate the potential use of SBRT for the treatment of node lesions from oligometastatic urothelial carcinoma. Here, we reported outcomes of a series of urothelial cancer patients with distant LNs metastases treated with SBRT at the Radiotherapy Unit of the University Hospital of Parma, Parma, Italy. The purpose of the present case series was to better characterize the efficacy of SBRT in both controlling progression of the lesions and/or delaying the beginning of a systemic treatment.
Methods
Patients from our single-institution center with oligometastatic urothelial carcinoma from January 2013 to December 2016 were screened. Oligometastatic urothelial carcinoma was defined by three or fewer metastatic lesions and no liver metastases, similarly to the classification proposed by Ogihara et al. 19 Among 41 advanced urothelial patients admitted to our department over the period, we identified seven (17%) patients who underwent SBRT for metastatic node lesions with the aim of either to consolidate the response to a previous systemic treatment or to delay the beginning of systemic chemotherapy. The remaining 34 patients did not receive SBRT, as they were not oligometastatic. We retrospectively collected data on patients' and lesions' characteristics, dose and timing of radiation therapy, chemotherapy regimen, and disease outcome. Recurrences were diagnosed by CT scan carried out every 3-6 months from surgery, and confirmed by 18-FDG PET/CT imaging, in accordance with our department guidelines. Every patient signed an informed consent before SBRT. All treated lesions were assessed by 18-FDG PET/CT or CT scan before and after SBRT (the first imaging after SBRT was carried out at 2 months and thereafter every 3 months) by a radiologist together with a nuclear medicine physician. SUV was used to measure increased accumulation of FDG compared with normal tissue. MTV was defined as the sum of the metabolic volume of all focal lesions, and was estimated before and after SBRT. TLG was defined as the product of the mean SUV and MTV, and was estimated before and after SBRT. Major and minor diameters of each lesion were measured at any time-point: within 2 months before the beginning of SBRT, within 3 months after the end of SBRT and approximately every 3 months until disease progression. Node lesions with a minor diameter ≤15 mm were considered target lesions, provided they were PET-positive. Target lesions were evaluated as follows: CR was defined as the disappearance of the target lesion; PR was defined as a minimum 30% decrease in minor diameter of the target lesion; PD was defined as a minimum 20% increase in the major diameter of the target lesion; stable disease was defined as a neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD. ORR was defined as the proportion of patients who experienced a PR at the first evaluation. LCR was defined as the proportion of patients who achieved stable disease or PR at first evaluation. Overall disease response was evaluated according to RECIST version 1.1. DoR was calculated as the time (in months) from the first response detection to the documented progression both of the treated lesion and of the whole disease. PFS was defined as the time (in months) from the RT starting to the documented PD or last follow up. OS was defined as the time (in months) from the RT starting to death or last follow up. We also calculated the LPFI, defined as the time from the beginning of RT to PD of the treated lesion, independently from the onset of new metastatic lesions. When the event did not occur at the time of last follow up, data were considered censored both for PFS and OS calculation. PFS and OS curves were summarized using the Kaplan-Meier method. We used descriptive statistics to show patients' and lesions' characteristics. Continuous variables were presented in mean, SD and SE. Categorical variables were expressed in frequencies with percentage. Student's t-test for pair data was used to compare means: P-value and 95% CIs were estimated for the evaluation of statistical significance for each comparison. Exclusion criteria were: negative 18-FDG PET/CT before RT treatment, previous RT for the same node lesion, and lack of clinical and/or imaging data.
Results

Patients' characteristics
A total of seven patients were enrolled in the study. Patients' characteristics are summarized in Table 1 . The median age of the population at diagnosis was 67 years. Five patients had bladder urothelial carcinoma, whereas two had upper tract urothelial carcinoma. All patients underwent radical surgery as primary treatment for urothelial carcinoma, and LNs were the sites of metastasis at recurrence in all cases. Four patients received SBRT before starting a systemic treatment (both in first-and in second-line); SBRT was administered to two patients after completing the first-line chemotherapy. Only one patient received SBRT during chemotherapy. The Bajorin risk score was 0 for five patients (71%), and 1 for the remaining two patients (29%). 18 Neoadjuvant chemotherapy was administered to one patient; after disease recurrence, first-line chemotherapy was given to all patients. The decision for first-line chemotherapy regimen was based on the patients fulfilling platinum eligibility criteria. 20 Among patients receiving first-line systemic treatment, five patients obtained PR as their best response. The median first-line treatment duration was 3.7 months (range 1.4-13.3), and the median number of cycles administered was five. Six patients (86%) experienced PD after first-line treatment and three patients received second-line therapy, consisting in vinflunine in all cases. Among three patients receiving second-line therapy, the Bellmunt risk score was 0 for two patients, and 2 for one patient. 21 
RT outcomes
Among seven patients included in the study, a total of 14 metastatic node lesions were treated with SBRT. We analyzed outcome data referring to 14 treated lesions; lesions' measures and outcomes are summarized in Table 2 . No treatment-related toxicities were documented after SBRT. Basal and post-treatment radiological evaluation examinations consisted of 18-FDG PET/CT scans for 13 lesions (93%). Seven lesions were stable at the time of beginning of RT, whereas the remaining seven lesions were progressing. The means of the major and minor diameters of the lesions before RT were 23 mm (SD AE12; SE AE3) and 19 mm (SD AE11; SE AE3), respectively. The mean SUV, TLG and MTV before RT were 6.1 (SD AE2.5; SE AE0.7), 30.4 (SD AE49.3; SE AE13.7) and 5.5 (SD AE3.7; SE AE1.0), respectively. The SBRT dose was chosen by the radiotherapist considering both the volume/site of each node lesion and the literature data about the dose able to promote activation of the immune system. 22, 23 The mean total dose of SBRT was 32 Gy (range 25-40 Gy); the mean number of fractions was 5.0, for a mean dose per fraction of 6.0 Gy, and the median time from the end of SBRT treatment and first radiological evaluation was 77.5 days. At first imaging evaluation, the means of the major and minor lesions diameters were 22 mm (SD AE17; SE AE4) and 16 mm (SD AE13; SE AE3), respectively, with a mean variation of À4% (À1 mm, 95% CI À5 to +2; P = 0.427) in major diameter and À16% (À3 mm, 95% CI À6 to 0 mm; P = 0.048) in minor diameter. Six lesions obtained a PR as their response to RT at the first evaluation examination; eight lesions remained stable and no lesion progressed, obtaining an ORR of 43% and an LCR of 100%. The lesions' outcome is shown in Figure 1 . Metabolic outcomes are referred to six out of seven patients, because one patient underwent CT scan as the first evaluation examination. At first assessment, the mean SUV was 1.8 (SD AE2.7; SE AE0.7), with a mean variation of À76% (À4.3, 95% CI À5.8 to À2.8; P < 0.001). The mean TLG and MTV at the first radiological assessment were 10.9 (SD AE30.7; SE AE8.5) and 2.5 (SD AE6.3; SE AE1.7), respectively. Of note, eight lesions obtained a complete metabolic response at the first evaluation 18-FDG PET/CT scan. At the second radiological evaluation, the mean SUV, TLG and MTV were 2.4, 17.0 PD is defined as a minimum 20% increase in the major diameter of the target lesion. PR is defined as a minimum 30% decrease in the minor diameter of the target lesion. Stable disease is defined as a neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD. -50 -48 Fig. 2 Lesions outcome after SBRT. Lesions are numbered according to the order they appeared in Table 1 . summarized in Figure 2 ; the PFS curve is shown in Figure 3a , and the median OS (Fig. 3b ) was 14.9 months (95% CI 12.3-17.5). Two patients were treated upfront with SBRT at the time of metastatic disease diagnosis, delaying the start of a first-line chemotherapy; furthermore, SBRT was successful in postponing the beginning of a second-line chemotherapy for the other two patients. Representative PET images of three irradiated node lesions, before and after RT, are provided in Figure 4 .
Discussion
To date, little is known about the role of RT for the treatment of oligometastatic urothelial cancer. To our knowledge, this is the first case series with the aim of exploring the efficacy of SBRT for the treatment of distant node metastases from oligometastatic urothelial cancer. In a recent retrospective study, Shah et al. investigated the efficacy of consolidative radiation therapy for residual disease after obtaining a PR to systemic treatment given at first relapse of urothelial cancer. 24 Of note, the most common sites of radiation were local nodes (64%). Median PFS from the starting of consolidation RT was 19 months and, surprisingly, eight patients out of 22 (36%) were alive and disease-free 6 years after radiation therapy, six of them treated for regional LNs. Interestingly, having only one LN site of metastasis was a statistically significant predictive factor. 24 Manig et al. also evaluated potential prognostic factors for survival among 63 patients with irradiated metastases of urothelial carcinoma. On univariate analysis, Karnofsky PS, initial N category and lower radiation doses (equivalent dose in 2 Gy fractions <20 Gy) were associated with worse survival. At multivariate analysis, the RT dose remained significant for survival. 25 In the present study, we described seven patients treated with SBRT for oligometastatic disease, with a total of 14 node-only lesions. All patients underwent radical surgery as the primary treatment, and two out of six patients were affected by upper tract urothelial carcinoma, which is known to be more aggressive than bladder cancer. The present results showed a robust radiological response to RT, with a statistically significant decrease in the minor diameter of treated lesions. ORR and LCR were 43% and 100%, respectively; furthermore, 6 months after irradiation, no irradiated lesion progressed. In the present study, SBRT was shown to be effective in reducing the metabolic activity of the treated node metastases; in fact, the metabolic activity of all evaluated lesions decreased in terms of SUV at the first 18-FDG PET/CT scan evaluation, with a mean SUV variation of À76%. Regarding time to progression, the median LPFI was longer than the median PFS, with an absolute difference of 8.5 months. Except for one patient, all treated node lesions remained stable or maintained response at the time of overall disease progression, implying a consistent prolonged effect of RT on irradiated lesions. Furthermore, SBRT was effective in delaying the start of a systemic treatment, both in first-line and in second-line treatment, for four patients. Despite SBRT treatment being carried out at not so high doses, the results obtained were certainly satisfactory. Not least, a greater reduction in lesion size was observed when higher doses of SBRT were administered (35/40 Gy vs 20/25 Gy), in line with the results of Manig et al., suggesting a potential impact of the administered RT dose on efficacy. 25 Limitations of the present study include the small sample size and the retrospective nature of the data collection. Furthermore, the study population was heterogeneous, as it included patients from different prognostic groups. Not least, SBRT was carried out at different time-points along the natural history of disease. Indeed, two patients received SBRT at the end of a first-line systemic treatment, four patients were treated with SBRT before starting first-line chemotherapy and only one patient received SBRT during chemotherapy. Regarding the two patients who received SBRT after chemotherapy, one patient experienced a response of irradiated lesions, which were stable at the end of chemotherapy. In this case, the interval from the end of systemic treatment to the start of SBRT was too long to justify a potential delayed effect of chemotherapy on the documented reduction of irradiated lesions (11 months). Regarding the patient who was treated with concurrent SBRT and chemotherapy (consisting of second-line vinorelbine), only the irradiated lesion remained stable at the first radiological evaluation examination, in contrast to the remaining node lesions that were progressing; this finding further supports the role of SBRT as the leading cause responsible for lesion's dimensional control and subsequent pain relief in this peculiar case.
Recently, immunotherapy has proven to be effective for the treatment of locally advanced or metastatic bladder cancer, both in the first-line and in second-line setting for platinum-refractory tumors; to date, five checkpoint inhibitors (atezolizumab, 26 avelumab, 27 durvalumab, 28 nivolumab 29 and pembrolizumab 30 ) received FDA approval for the treatment of advanced urothelial carcinoma, opening a new landscape for disease management. Furthermore, a phase I study of anti-PD1 pembrolizumab plus RT for the treatment of advanced platinum-refractory urothelial carcinoma will evaluate the potential role of combination regimen. 31 Nivolumab and atezolizumab are also currently being investigated in combination with RT for metastatic disease. 32 On the basis of preclinical evidence and clinical reports of the RT-induced abscopal effect, a future role of RT in combination with immunotherapy for metastatic disease seems appealing and, in our opinion, should be considered for future research in the metastatic setting. 33 Based on the present results, given the long-term effect of RT on node lesions, we can only hypothesize that SBRT could be taken into account for highly-selected patients with small tumor burden, especially for those affected by node-only disease. Even if definitive conclusions cannot be drawn, we speculate that SBRT could be useful in delaying the beginning of a systemic treatment in this population, but the present findings should be further validated by a prospective study. Furthermore, on the basis of existing evidence of the RT-induced abscopal effect, the present hypothesisgenerating study could support a future role of RT in combination with immunotherapy for metastatic disease.
